The Pharmacy Times® Hepatitis Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of distinct diseases that cause inflammation of the liver, including hepatitis A, B, C, and D.
August 18th 2025
FDA approves semaglutide for treating MASH, offering new hope for affected individuals.
Merck Discontinues 2 HCV Clinical Programs
September 30th 2017This decision was made based on a review of available phase 2 efficacy data and in consideration of the evolving marketplace and the growing number of treatment options available for patients with chronic HCV infection, including elbasvir and grazoprevir (Zepatier).
Read More